EUCTR2015-003106-16-SE进行中（未招募）1 期
Immunogenicity of influenza vaccination among breast cancer patientstreated with trastuzumab in adjuvant setting
Antonis Valachis0 个研究点开始时间: 2015年10月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Patients with stage I-II or operable stage III HER2 – positive (FISH or CISH with amplification and / or +++ in immunohistochemistry) breast cancer, after breast cancer surgery (breast-conserving surgery or mastectomy), without any clinical or radiological signs of distant metastasis (radiologic work-up is not necessary; according to local guidelines).
- •2.Woman > 18 years of age.
- •3.Radiotherapy (local or locoregional) prior or during the study inclusion period is allowed.
- •4.Endocrine therapy (tamoxifen or aromatase inhibitors) is allowed.
- •5.Prior neoadjuvant or adjuvant chemotherapy is allowed only if the time period between the last cycle of chemotherapy and inclusion to the study is at least 1 month.
- •6.Both intravenous and subcutaneous formulations of trastuzumab are allowed.
- •7.Able to read, understand, and sign informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.Inflammatory breast cancer or inoperable stage III breast cancer.
- •2.Presence of distant metastases.
- •3.Possible change of anti-cancer treatment before the first evaluation of immunogenicity following the first injection (to avoid bias related to any therapy changes).
- •4.History of another malignancy within the last 5 years except cured basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix.
- •5.Neutrophils < 1.5 x 109/L
- •6.Left ventricular ejection fraction (LVEF) less than 50% (or under the institutional normal reference range) assessed by echocardiography or isotope cardiography.
- •7.Fever at time of vaccination (temperature of = 38.5 C).
- •8.Known allergic reaction to any of the components of the vaccine (e.g. hypersensitivity to egg protein).
- •9.Treatment with cortison (> 15 mg prednisolone or equivalent daily) or any other immunosuppressive agent at the moment of vaccination.
- •10.Any other immunosuppressive disease (such as HIV infection, renal insufficiency, cirrhosis).
- •11.History of clinically or virologically confirmed influenza infection in the previous 6 months.
- •12.Any other immunization carried out in the 3 weeks before the first injection or planned in the following month.
- •13.Pregnant or lactating women. Positive serum pregnancy test in women of childbearing potential within seven days prior to the first dose of study drug.
- •14.Women of childbearing potential unless using a reliable and appropriate contraceptive method (hormonal methods: combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices; non-hormonal methods: intrauterine device, tubal ligation, complete abstinence, barrier method (condoms, diaphragm) also in conjuction with spermicidal jelly; total abstinence). Women must have been amenorrheic for at least 12 months prior to study entry to be considered postmenopausal and to have no childbearing potential. Women of childbearing potential (menstruating within 12 months of study entry), or with no hysterectomy and age < 55, must have a negative pregnancy test at baseline.
- •15.Unwilling or unable to comply with the protocol for the duration of the study.
- •For the healthy control group, we will include women > 18 years old (employees of participating hospitals that voluntarily participate in the yearly influenza vaccination campaign for health care personnel) that have not been diagnosed with breast cancer, they fulfill inclusion criterion 7, and do not fulfill any of the exclusion criteria 7-15.
研究者
相似试验
已完成
不适用
Research on influenza vaccine immunogencity in infants.influenzaJPRN-C000000241The Research Foundation for Microbial Diseases of Osaka University200
终止
不适用
sing influenza vaccination to understand and improve immune responses to vaccination in patients with chronic obstructive pulmonary disease (COPD) and healthy older people.Chronic Obstructive Pulmonary DiseaseInfluenza viral diseaseRespiratory - Chronic obstructive pulmonary diseaseInfection - Other infectious diseasesACTRN12620000830998Princess Alexandra Hospital171
已完成
不适用
Evaluation of immunogenicity of influenza vaccine in childreKCT0006127Korea University Ansan Hospital130
已完成
不适用
The effectiveness of Influenza vaccination among pregnant women in Nakhon Phanom province, ThailandTCTR20201014004akhon phanom hospital foundation1,858
终止
不适用
Boosting influenza vaccine responses in the elderly using a brief bout of exerciseAdvanced ageInfluenza vaccine responsesInflammatory and Immune System - Normal development and function of the immune systemACTRN12611001119987niversity of Sydney96